Dexamethasone protects neonatal hypoxic-ischemic brain injury via L-PGDS-dependent PGD2-DP1-pERK signaling pathway

PLoS One. 2014 Dec 4;9(12):e114470. doi: 10.1371/journal.pone.0114470. eCollection 2014.

Abstract

Background and purpose: Glucocorticoids pretreatment confers protection against neonatal hypoxic-ischemic (HI) brain injury. However, the molecular mechanism remains poorly elucidated. We tested the hypothesis that glucocorticoids protect against HI brain injury in neonatal rat by stimulation of lipocalin-type prostaglandin D synthase (L-PGDS)-induced prostaglandin D2 (PGD2)-DP1-pERK mediated signaling pathway.

Methods: Dexamethasone and inhibitors were administered via intracerebroventricular (i.c.v) injections into 10-day-old rat brains. Levels of L-PGD2, D prostanoid (DP1) receptor, pERK1/2 and PGD2 were determined by Western immunoblotting and ELISA, respectively. Brain injury was evaluated 48 hours after conduction of HI in 10-day-old rat pups.

Results: Dexamethasone pretreatment significantly upregulated L-PGDS expression and the biosynthesis of PGD2. Dexamethasone also selectively increased isoform pERK-44 level in the neonatal rat brains. Inhibitors of L-PGDS (SeCl4), DP1 (MK-0524) and MAPK (PD98059) abrogated dexamethasone-induced increases in pERK-44 level, respectively. Of importance, these inhibitors also blocked dexamethasone-mediated neuroprotective effects against HI brain injury in neonatal rat brains.

Conclusion: Interaction of glucocorticoids-GR signaling and L-PGDS-PGD2-DP1-pERK mediated pathway underlies the neuroprotective effects of dexamethasone pretreatment in neonatal HI brain injury.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Animals, Newborn
  • Brain / drug effects
  • Brain / enzymology
  • Dexamethasone / pharmacology
  • Dexamethasone / therapeutic use*
  • Drug Evaluation, Preclinical
  • Enzyme Induction / drug effects
  • Female
  • Hypoxia-Ischemia, Brain / enzymology
  • Hypoxia-Ischemia, Brain / prevention & control*
  • Intramolecular Oxidoreductases / physiology*
  • Lipocalins / physiology*
  • MAP Kinase Signaling System*
  • Male
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Prostaglandin D2 / metabolism
  • Rats, Sprague-Dawley
  • Transcription Factor DP1 / metabolism
  • Up-Regulation

Substances

  • Lipocalins
  • Neuroprotective Agents
  • Transcription Factor DP1
  • Dexamethasone
  • Intramolecular Oxidoreductases
  • prostaglandin R2 D-isomerase
  • Prostaglandin D2